Video

Charting the progress of BenevolentAI’s collaboration with AstraZeneca

In April 2019, we announced a collaboration with AstraZeneca to design and develop new treatments for disease beginning with chronic kidney disease and idiopathic pulmonary fibrosis.

By combining our AI and machine learning capabilities with AstraZeneca’s disease area expertise and large, diverse datasets, we hope to improve our understanding of complex disease biology and more quickly identify new potential drug targets.

Our biologists, chemists, engineers, informaticians and data scientists, are working together with our peers at AstraZeneca  to provide new opportunities in understanding and targeting these diseases. In this video, scientists from the centre of the project chart the progress of the collaboration and share their reflections on changing the way we do drug discovery, to enable more efficient and data-driven development  of new medicines.

In our opinion,  partnerships aren’t forged on paper. You can’t write a partnership into being. It has to be based on a professional respect, shared ambition and a common set of values. For us this is the fusion of human expertise with technological innovation. That collision of capabilities is what will help us work  together to  help more people live longer, healthier lives.


More Posts

You Might Also Like

News
BenevolentAI’s platform-derived hypothesis for COVID-19 treatment validated in US NIAID randomised control trial
NIAID trial shows baricitinib in combination with remdesivir reduces the recovery time in patients hospitalised with COVID-19, validating BenevolentAI’s AI-derived hypothesis.
Sep 14, 2020
Blog
Building the next generation of leaders with Circl
BenevolentAI Director of Talent Acquisition and Development, Yasmina Rahiman, explores the power of coaching for leadership development in technology.
Aug 21, 2020
News
Clinical data validates BenevolentAI's AI predicted hypothesis for baricitinib as a potential treatment for COVID-19
Research published in EMBO Molecular Medicine confirms AI predictions for anti-viral and anti-cytokine signalling effects of baricitinib in critically hospitalised COVID-19 patients
Jul 1, 2020
News
COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair
David Sinclair and colleagues review our recent publication in the EMBO Molecular Medicine Journal in support of our AI-derived hypothesis for a potential treatment of COVID-19.
Jul 1, 2020
Video
How do we get the next 10 years right? w/ Joanna Shields, CogX
“We need leaders with empathy who care about their fellow citizens and are prepared to work to end injustice and create opportunities for all". Our CEO Joanna Shields opens CogX 2020 sharing inspiration for the next decade.
Jun 8, 2020
Blog
Kindness matters: mental health and wellbeing through COVID-19 and beyond
To conclude Mental Health awareness week, we share some thoughts about the power of kindness and how building a culture of openness will help shape the future of business.
May 27, 2020